Evidence map›Paper›PMID 26681145›Full record

ArticleEye (London, England)2016

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

L C Olmos, M S Sayed, A L Moraczewski, S J Gedde, P J Rosenfeld, W Shi, W J Feuer, R K Lee

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. [Secondary open-angle glaucoma: pseudoexfoliative glaucoma, pigmentary glaucoma and neovascular glaucoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022
    Review
  11. Etiology, pathogenesis, and diagnosis of neovascular glaucoma.International journal of ophthalmology · 2022
    Review
  12. Article
  13. Article
  14. [Ocular ischemic syndrome : An important differential diagnosis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

L C OlmosBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
M S SayedBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
A L MoraczewskiBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
S J GeddeBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
P J RosenfeldBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
W ShiBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
W J FeuerBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
R K LeeBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Dmitry V Ivanov · 2004 to 2026
$12.2M
NEI NIH HHS P30 EY014801NEI NIH HHS P30EY014801
6 · The paper itself

Abstract

aimsTo compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study.

methodsThe study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP).

resultsAt the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P<0.001) in bevacizumab treated NVG eyes.

conclusionsAlthough bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP.

Indexed as

AgedAngiogenesis InhibitorsAntihypertensive AgentsBevacizumabFemaleFollow-Up StudiesGlaucoma, NeovascularHumansIntraocular PressureIntravitreal InjectionsLaser CoagulationMaleMiddle AgedRetrospective StudiesVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsAntihypertensive AgentsBevacizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID26681145
PMCPMC4791706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.